The selective inhibition of vascular permeability factor (VPF) expression in ovarian carcinoma cell lines by a gonadotropin-releasing hormone (GnRH) agonist

T. A. Olson, D. Mohanraj, Sundaram Ramakrishnan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.

Original languageEnglish (US)
Pages (from-to)905-910
Number of pages6
JournalInternational Journal of Oncology
Volume6
Issue number4
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Vascular Endothelial Growth Factor A
Carcinoma
Cell Line
Angiogenesis Inducing Agents
Conditioned Culture Medium
Endothelium
Neoplasms
Hormones
Messenger RNA
Peptides

Keywords

  • Gonadotropin-releasing hormone (GnRH)
  • Ovarian cancer
  • Vascular endothelial growth factor (VEGF)
  • Vascular permeability factor (VPF)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{c888572e13f845b387c3659498057bf8,
title = "The selective inhibition of vascular permeability factor (VPF) expression in ovarian carcinoma cell lines by a gonadotropin-releasing hormone (GnRH) agonist",
abstract = "GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.",
keywords = "Gonadotropin-releasing hormone (GnRH), Ovarian cancer, Vascular endothelial growth factor (VEGF), Vascular permeability factor (VPF)",
author = "Olson, {T. A.} and D. Mohanraj and Sundaram Ramakrishnan",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "905--910",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - The selective inhibition of vascular permeability factor (VPF) expression in ovarian carcinoma cell lines by a gonadotropin-releasing hormone (GnRH) agonist

AU - Olson, T. A.

AU - Mohanraj, D.

AU - Ramakrishnan, Sundaram

PY - 1995/1/1

Y1 - 1995/1/1

N2 - GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.

AB - GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.

KW - Gonadotropin-releasing hormone (GnRH)

KW - Ovarian cancer

KW - Vascular endothelial growth factor (VEGF)

KW - Vascular permeability factor (VPF)

UR - http://www.scopus.com/inward/record.url?scp=0028959339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028959339&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 905

EP - 910

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -